Vlad Coric, M.D., CEO of Biohaven, added, "Receiving the orphan drug designation request for spinocerebellar ataxia supports our global development strategy and goal of providing improved therapies for patients suffering from neurologic disorders with ...
By clicking “submit,” you agree to receive emails from Ability Today and accept our web terms of use and privacy and cookie policy.